The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM
{{output}}
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median survival of under 15 months and no effective treatment after recurrence. A recent phase 1 trial of intracerebroventricular bivalent chimeric antigen receptor (CAR) T c... ...
